NCT06038929招募中不适用
REVEAL - Research Evaluating Vagal Excitation and Anatomical Linkages Gastric Emptying Ancillary Project: Effect of Vagal Nerve Stimulation on Gastric Motor Functions
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Mayo Clinic
- 入组人数
- 16
- 试验地点
- 4
- 主要终点
- Gastric emptying T1/2
研究概览
简要总结
The specific aim of this study is to compare simultaneous assessment of gastric emptying and gastric accommodation in response to a caloric meal In patients who have previously undergone activation of left cervical VNS for the treatment of medication-resistant depression. Our hypothesis is that cervical VNS increases gastric accommodation and accelerates gastric emptying compared to a bank of healthy control data.
详细描述
Objectives To compare simultaneous assessment of gastric emptying and gastric accommodation in response to the same caloric meal in patients who have undergone activation of left cervical Vagal Nerve Stimulation.
Design and Outcomes Single cohort study in 12 Vagus Nerve Stimulant-implanted subjects with drug-resistant depression, aged 18 years or older who were consented for the main VESPA REVEAL Common Study Protocol.
There is only 1 visit needed, with an average time commitment of 4.5 hours. Participants will have completed their planned VESPA REVEAL study visits Interventions and Duration In this single cohort study in 12 Vagus Nerve Stimulant-implanted subjects, each participant will undergo combined gastric emptying/accommodation test after completing the Visits required in CSP
Sample Size and Population
Sample size assessment. This will be based on results of the primary endpoints in our Mayo Clinic lab. We expect 80% power, α=0.05, assuming unpaired t-test analysis with n=12 in patients receiving VNS compared to the healthy control data (n=300 for both gastric emptying and gastric volume . Demonstrable differences (Table 1) will be based on the variation (SD) observed from our Mayo Clinic prior studies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •GENERAL criteria
- •Participant has a prior implantable stimulation device other than a VNS device for the clinical indication of refractory focal Epilepsy or for depression.
- •Participant currently uses or during the study is expected to use short-wave diathermy, microwave, diathermy, or therapeutic ultrasound diathermy.
- •Participant has a diagnosis of Substance Use Disorder as defined by DSM-5 without sustained remission of 12 months or longer.
- •Patient participated in another drug or device trial within the preceding 30 days (other than REVEAL studies).
- •Participant has been hospitalized for a psychiatric condition within the preceding 6 months or has had a history of psychosis within the preceding two years (excluding post-ictal psychosis).
- •Participant has experienced unprovoked status epilepticus in the preceding year.
- •Participant is not able or willing to use their dominant arm, or either upper arm circumference is greater than 50 cm.
- •Any other clinical reasons deemed by the investigators of the study for which the participant would not be an appropriate candidate for the study, such as peripheral vascular disease, Raynaud's phenomenon, orthostatic hypotension (OH), postural orthostatic tachycardia syndrome (POTS), uncontrolled obstructive sleep apnea (OSA), chronic obstructive pulmonary disease (COPD), or uncontrolled diabetes or pregnancy
- •Participant with vocal cord paralysis
- •Participant cannot speak and read English.
- •Participant is pregnant.
- •Prohibited Therapy During Study Period: We will exclude patients on immunosuppressants, beta blockers, anticholinergics, and clonidine. Consultation with primary providers and amending some of these therapies may be allowed only if clinically indicated. In that case, participants will have to be stable on their new medication for at least one month prior to implant.
- •A body weight of over 350 pounds or 159 kilograms due to equipment limitations used in the measurements of gastric accommodation and emptying.
- •An inability to eat eggs whether due to an allergy, intolerance, or strong dislike. The gastric emptying test meal contains eggs that are labeled with radioisotope. Other food substitutions for the toast, butter and milk may be made only if prior approval is given by Dr. Camilleri.
- •Any other factor that may impact participant safety or compliance as per PI.
- •Since participants with pVNS will be recruited from the CSP study at U Minnesota, it is important to specify the inclusion and exclusion criteria for participants with drug-resistant epilepsy or drug-resistant depression who entered the CSP study:
- •Inclusion Criteria for Participants With Major Depressive Disorder That Have a Previously Implanted VNS Device
- •Participant must be at least 18 years old.
- •Participant must have the capacity to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization.
- •Participant must be enrolled in an active health insurance plan that will cover the costs associated with standard health care services and injuries.
- •Participant must have been previously implanted with a VNS device for the clinical indication of Major Depressive Disorder (MDD).
- •Participant must have a score on the baseline administration of the Montgomery-Åsberg Depression Rating Scale (MADRS) of ≥
- •Participant must be able and willing to complete the evaluations and procedures described in the study protocol.
- •Participant must be able and willing to follow the stipulations regarding concomitant medications and excluded medications described in section 5.3 of the study protocol.
- •Participant that is of childbearing potential must be adequately protected from conception or willing to use an acceptable method of birth control over the entire study duration (acceptable birth control includes abstinence, barrier methods, hormonal methods, sterilization and fertility awareness).
- •Exclusion Criteria for Participants With Major Depressive Disorder That Have a Previously Implanted VNS Device
- •Participant has a prior implantable stimulation device, other than a VNS device for the clinical indication of Major Depressive Disorder (MDD).
- •Participant currently uses or is expected during the study to use short-wave diathermy, microwave, diathermy, or therapeutic ultrasound diathermy.
- •Participant is judged by the investigator to be acutely suicidal (e.g. has made specific plans or preparations to commit suicide or as indicated by the Sheehan Suicidality Tracking Scale) within the last 30 days prior to study enrollment.
- •Participant has made a suicide attempt within the previous 6 months from study enrollment.
- •Participant has a history of one or more schizophrenia-spectrum or other psychotic disorders including schizophrenia, schizoaffective disorder, delusional disorder, or a current or lifetime major depressive episode that includes psychotic features (commonly referred to as psychotic depression) according to the MINI criteria.
- •Participant has a history of significant borderline or severe personality disorder as determined by clinical judgment.
- •Participant has an active primary diagnosis of obsessive-compulsive, eating, or post-traumatic stress disorder based on the MINI criteria.
- •Participant has a diagnosis of Substance Use Disorder as defined by DSM-5 without sustained remission of 12 months or longer.
- •Participant has a presence of any type of dementia, major neurocognitive disorder, or cognitive or psychiatric deficit as determined by clinical judgment.
- •Participant has a history of rapid cycling bipolar disorder I or II.
- •Participant currently receives treatment with another investigational device or investigational drug other than the REVEAL study (or a REVEAL ancillary project or sub-study) or has participated in another drug or device trial within the preceding 30 days before enrollment.
- •Participant is not able or willing to use their dominant arm, or either upper arm circumference is greater than 50 cm.
- •Participant does not speak English.
- •Participant is pregnant.
- •Any other clinical reasons deemed by the investigators of the study for which the participant would not be an appropriate candidate for the study, such as peripheral vascular disease, Raynaud's phenomenon, orthostatic hypotension (OH), postural orthostatic tachycardia syndrome (POTS), uncontrolled obstructive sleep apnea (OSA), chronic obstructive pulmonary disease (COPD), or uncontrolled diabetes.
- •Inclusion Criteria for Participants With Drug Resistant Epilepsy That Have a Previously Implanted VNS Device
- •Participant must be at least 18 years old.
- •Participant must have the capacity to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization.
- •Participant must be enrolled in an active health insurance plan that will cover the costs associated with standard health care services and injuries.
- •Participant must have been previously implanted with a VNS device for the clinical indication of drug resistant epilepsy.
- •Participant has not had demonstrable benefit from the implanted VNS device in terms of epilepsy (seizure frequency or seizure severity) or related epilepsy comorbidities (mood, cognition, quality of life), with no definite improvement or suboptimal improvement in seizure control.
- •Apart from epilepsy, the participant should be medically and neurologically stable.
- •Participant must be able and willing to complete the evaluations and procedures described in the study protocol.
- 另有 14 项未显示
结局指标
主要结局
Gastric emptying T1/2
时间窗: during 4 hour gastric emptying test
time to empty 50% of the whole stomach contents
Gastric accommodation
时间窗: during first 1 hour of gastric emptying test
gastric delta volume (postprandial minus fasting) for the whole stomach
次要结局
- Fasting whole volume volume(baseline)
- Gastric emptying 25%(1 day (during gastric emptying test))
- Gastric emptying at 2 hours(2 hours (during gastric emptying test))
- Gastric emptying lag time(1 day (during gastric emptying test))
- Gastric emptying at 4 hours(4 hours (during gastric emptying test))
- Fasting proximal gastric volume(baseline)
- Postprandial whole gastric volume(10-30 minutes after meal ingestion)
- Postprandial proximal gastric volume(10-30 minutes after meal ingestion)
研究者
Michael Camilleri, MD
Professor of Medicine, Pharmacology and Physiology
Mayo Clinic
研究点 (4)
Loading locations...
相似试验
招募中
Unknown
Studying the time taken for stomach to get empty after taking food by performing an ultrasound in normal weight and overweight pregnant women who are planned for delivery by surgery.CTRI/2023/09/057875Maulana Azad Medical College
已完成
不适用
Flintstone Foods 1ObesityNCT01925053Quadram Institute Bioscience4
已完成
不适用
Gastric Layering StudyHealthy VolunteersNCT01565057Quadram Institute Bioscience10
进行中（未招募）
1 期
Impact on gastric emptying measured by antral gastric ultrasound of erythromycin administration in stroke patients with indication for mechanical thrombectomy.Patient presenting to the neuroradiological emergency room with an ischemic stroke and requiring interventional neuroradiology for stroke. Only patients with significant gastric contents on ultrasound (stomach is full: antral area >340mm²) according to a measurement taken before the start of the procedure in the supine position will be randomized in the study.CTIS2023-508120-35-00Hospital Foch84
已完成
不适用
A study to observe the movement and time required by Mesalamine tablet manufactured by Hetero Healthcare Ltd to reach colon area.CTRI/2022/01/039171Hetero Healthcare Ltd6